Cargando…

Ozanimod Maintenance Therapy After Cyclosporine Induction in Acute Severe Ulcerative Colitis

Ozanimod has recently received US Food and Drug Administration approval for moderate-to-severe ulcerative colitis. Treatment of acute severe colitis remains a clinical challenge, and although many patients respond to cyclosporine therapy, there remains a relative paucity of maintenance options. This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cohen, Nathaniel A., Dalal, Sushila R., Choi, David, Rubin, David T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302285/ https://www.ncbi.nlm.nih.gov/pubmed/35919406 http://dx.doi.org/10.14309/crj.0000000000000832

Ejemplares similares

Ozanimod: A Review in Ulcerative Colitis
por: Paik, Julia
Publicado: (2022)

Combining Cyclosporine With Ustekinumab in Acute Severe Ulcerative Colitis
por: Shaffer, Seth R., et al.
Publicado: (2021)

Correction to: Ozanimod: A Review in Ulcerative Colitis
por: Paik, Julia
Publicado: (2022)

Ozanimod-Associated Iatrogenic Kaposi Sarcoma in a Patient With Ulcerative Colitis
por: Sandlow, Sarah, et al.
Publicado: (2023)

Use of Serum Infliximab Level Prior to Cyclosporine Salvage Therapy in Severe Ulcerative Colitis
por: Chapman, Christopher G., et al.
Publicado: (2014)

Su1500: COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
por: Dubinsky, Marla C., et al.
Publicado: (2022)

Ozanimod Therapy in a Patient With Ulcerative Colitis and Multiple Sclerosis: Hitting 2 Birds With 1 Stone
por: Vuyyuru, Sudheer K., et al.
Publicado: (2023)

Network pharmacology and in silico pharmacokinetic prediction of Ozanimod in the management of ulcerative colitis: A computational study
por: Sivasakthi, Priya, et al.
Publicado: (2022)

A Clinical Predictive Model for One-year Colectomy in Adults Hospitalized for Severe Ulcerative Colitis
por: Zafer, Maryam, et al.
Publicado: (2021)

Su1480: TREATMENT-EMERGENT COVID-19 INFECTIONS IN OZANIMOD ULCERATIVE COLITIS AND MULTIPLE SCLEROSIS CLINICAL TRIALS
por: Ungaro, Ryan C., et al.
Publicado: (2022)

Dramatic Deep and Durable Remission of Acute Fulminant Ulcerative Colitis Achieved with Cyclosporine in a Patient Who Failed the Induction Intravenous Phase of Cyclosporine
por: Philippou, Alicia, et al.
Publicado: (2021)

Ozanimod for multiple sclerosis
Publicado: (2021)

Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial
por: Rubin, David T., et al.
Publicado: (2016)

Successful cyclosporin and ustekinumab combination therapy in a patient with severe steroid-refractory ulcerative colitis
por: Ganzleben, Ingo, et al.
Publicado: (2020)

Salvage Therapy in Acute Severe Ulcerative Colitis: Current Practice and a Look to the Future
por: Tamir-Degabli, Natalie, et al.
Publicado: (2023)

Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab
por: Chen, An-Yu, et al.
Publicado: (2019)

Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study
por: Sandborn, William J, et al.
Publicado: (2021)

Development of ulcerative colitis under the immunosuppressive effect of cyclosporine
por: Passfall, J., et al.
Publicado: (1992)

Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis
por: Feuerstein, Joseph D., et al.
Publicado: (2016)

"Hit smart and early" - MS-Therapie mit Ozanimod
por: Ottenjann, Henrike
Publicado: (2023)

Does the Cyclosporine Still Have a Potential Role in the Treatment of Acute Severe Steroid-Refractory Ulcerative Colitis?
por: Eun, Chang Soo, et al.
Publicado: (2015)

Infliximab is more effective than cyclosporine as a rescue therapy for acute severe ulcerative colitis: a retrospective single-center study
por: Grazie, Marco Le, et al.
Publicado: (2021)

Cyclosporine-Induced Kaposi Sarcoma in a Patient With Ulcerative Colitis
por: Clarke, Lindsay M., et al.
Publicado: (2021)

"Hit smart and early" mit Ozanimod
por: Ottenjann, Henrike
Publicado: (2023)

Tacrolimus for Remission Induction and Maintenance Therapy in Patients with Ulcerative Colitis: A Retrospective Evaluation Study
por: Ito, Ayumi, et al.
Publicado: (2016)

Efficacy of Switching to Adalimumab for Maintenance of Remission Following Induction Therapy with Tacrolimus in Patients with Ulcerative Colitis
por: Numa, Keijiro, et al.
Publicado: (2023)

Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn’s disease and ulcerative colitis
por: Hashash, Jana G., et al.
Publicado: (2021)

Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: A meta-analysis
por: Jia, Xuemei, et al.
Publicado: (2020)

Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies
por: Panés, Julian, et al.
Publicado: (2018)

Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies
por: Panés, Julian, et al.
Publicado: (2019)

Intravenous tacrolimus is a superior induction therapy for acute severe ulcerative colitis compared to oral tacrolimus
por: Shimizu, Hiromichi, et al.
Publicado: (2021)

Neuroprotection by Ozanimod Following Intracerebral Hemorrhage in Mice
por: Wang, Fei, et al.
Publicado: (2022)

Comparable Long-Term Outcomes of Cyclosporine and Infliximab in Patients With Steroid-Refractory Acute Severe Ulcerative Colitis: A Meta-Analysis
por: Szemes, Kata, et al.
Publicado: (2020)

Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data
por: Danese, Silvio, et al.
Publicado: (2023)

Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes
por: Magro, Fernando, et al.
Publicado: (2023)

Infliximab versus cyclosporine for severe ulcerative colitis refractory to steroids: A protocol for systematic review and meta-analysis
por: Wu, Dongjie, et al.
Publicado: (2018)

Changes in energy metabolism after induction therapy in patients with severe or moderate ulcerative colitis
por: Inoue, Mai, et al.
Publicado: (2015)

Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
por: Midha, Vandana, et al.
Publicado: (2018)

Acute Severe Ulcerative Colitis: Optimal Strategies for Drug Therapy
por: Nakase, Hiroshi
Publicado: (2023)

Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis)
por: Probert, Christopher SJ, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_emb5hj3cbrvo22dj3ve6cc9c2r